scispace - formally typeset
A

Alan P. Kozikowski

Researcher at University of Illinois at Chicago

Publications -  198
Citations -  11235

Alan P. Kozikowski is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Nicotinic agonist & Cancer. The author has an hindex of 55, co-authored 198 publications receiving 9996 citations. Previous affiliations of Alan P. Kozikowski include University of Chicago & University of Illinois at Urbana–Champaign.

Papers
More filters
Journal ArticleDOI

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.

TL;DR: Tubastatin A, a hydroxamate-containing HDAC6-selective compound, displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogues to neurodegenerative conditions.
Journal ArticleDOI

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

TL;DR: An increase of α-tubulin acetylation induced by pharmacological inhibition of histone deacetylase 6 (HDAC6) corrected the axonal transport defects caused by HSPB1 mutations and rescued the CMT phenotype of symptomatic mutant H SPB1 mice.
Journal ArticleDOI

HDAC6 is a target for protection and regeneration following injury in the nervous system

TL;DR: It is shown that pan-HDAC inhibition not only promotes neuronal protection against oxidative stress, a common mediator of injury in many neurological conditions, but also promotes neurite growth on myelin-associated glycoprotein and chondroitin sulfate proteoglycan substrates.
Journal ArticleDOI

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.

TL;DR: Two lead iodine compounds were radiolabeled with (123)I and (131)Iand demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.